Yi Lin

Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium

J. Vose, L. Lekakis, M. Lunning, 2023, Blood advances.

Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma Immunotherapy Consortium Real World Experience

S. Sidana, S. Atrash, A. Afrough, 2024, Transplantation and Cellular Therapy.

AXICABTAGENE CILOLEUCEL (AXI‐CEL; KTE‐C19) IN PATIENTS WITH REFRACTORY AGGRESSIVE NON‐HODGKIN LYMPHOMAS (NHL): PRIMARY RESULTS OF THE PIVOTAL TRIAL ZUMA‐1

D. Miklos, C. Jacobson, N. Bartlett, 2017 .

Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality

Yucai Wang, E. Bachy, G. Iacoboni, 2024, Blood advances.